Sibold William John sold $6.2M of MDGL

Sibold William John (President and CEO) sold 11,583 shares of MADRIGAL PHARMACEUTICALS, INC. (MDGL) at an average of $538.65 ($527.88–$546.38, $6.24M total) across 24 trades over 2026-09-09 to 2026-09-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sibold William John
Published Sep 11, 2026, 8:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 8:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MDGL
Bearish
medium confidence
Mentioned
$MDGL
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MDGLBearishLow
01

Why it matters

Provides fresh data on insider sentiment for MDGL.

02

Market read

First public disclosure of a multi‑million insider sell; modest relevance for traders monitoring MDGL.

03

What to watch

CEO may be diversifying holdings; 10b5‑1 plans can mask timing motives.

Relevance 5/10Novelty 5/10Timing: after‑hours filing on Sep 11

Background

Form 4 filing discloses insider transactions required by SEC.

Company-level read

Ticker impact

$MDGLBearishMedium confidence
Context

CEO William John Sibold sold $6.2M of MDGL shares via a 10b5‑1 plan, reducing his stake to 197,746 shares.

Expected impact

Potential modest downside of 2‑4% if market interprets as lack of confidence.

Evidence & confidence

Sale size is moderate and executed under a pre‑arranged plan, limiting immediate signal strength.

Market effects

Biotech sector may see slight caution as insider activity is monitored.

Limited to US biotech investors.

Minimal global impact.

Counterpoint

Sale could be routine liquidity management, not a negative signal.

Key entities

  • Madrigal Pharmaceuticals, Inc.

    Biotech firm developing therapies for metabolic diseases.

  • William John Sibold

    President and CEO of MDGL.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MDGLMedAI 8/10

BAKER BROS. ADVISORS LP (BAKER FELIX, BAKER JULIAN) purchased $35.0M of MDGL (indirect holdings)

BAKER BROS. ADVISORS LP purchased 91,806 indirectly-held shares of MADRIGAL PHARMACEUTICALS, INC. (MDGL) at an average of $381.49 ($366.99–$396.61, $35.02M total) across 5 trades over 2026-11-04 to 2026-11-06. Filed jointly with Baker Bros. Advisors (GP) LLC (Director), BAKER FELIX (Director), BAKER JULIAN (Director), 667, L.P. (Director) and Baker Brothers Life Sciences LP (Director).

$MDGLMed

Madrigal reports real-world data on liver disease drug Rezdiffra

Madrigal Pharmaceuticals (MDGL) presented real-world data on its liver disease drug Rezdiffra at a liver disease conference. Studies showed 37% to 55% of patients achieved at least 25% improvement in liver stiffness after a year, with 83% to 93% improving or stabilizing. Safety findings were consistent with clinical trials. Rezdiffra is approved for treating adults with MASH.

$MDGLMedAI 8/10

Madrigal (MDGL) Q3 2026 Earnings Call Transcript

Madrigal Pharmaceuticals (MDGL) reported Q3 2026 net sales of $431M, up 50% YoY, driven by demand for Rezdiffra. The company had 55,850 active Rezdiffra patients, nearly double the previous year. Madrigal expects the U.S. F2/F3 MASH market to grow 30% by year-end, with Rezdiffra penetrating about 1% of the total opportunity.